Bioprinting

CDC to deploy HP bioprinters to accelerate testing of new antibiotics

Through a new pilot program, HP bioprinters will be sent to four labs across the US for antibiotics testing

The challenge to develop new antibiotics is real and pressing. Thankfully, researchers are not going at it alone, as HP Inc. recently signed on to participate in a pilot program with the Centers for Disease Control and Prevention (CDC). The program, which seeks to create and test new antibiotics for combatting antimicrobial resistant bacteria, will utilize HP bioprinters for producing pharmaceutical samples.

Though not strictly 3D bioprinting, the effort is still an interesting project for printing specialists HP. In the pilot project, the company explains, the CDC will deploy HP D300e Digital Dispenser BioPrinters to four regional labs in the Antibiotic Resistance Lab Network. Once installed, the machines will be used to rapidly turn out samples for the purpose of developing new drug testing methods.

“Bacteria continuously develop new ways to resist antibiotics—once a drug is approved for use, the countdown begins until resistance emerges,” explained Jean Patel, PhD, Science Team Lead, Antibiotic Resistance Coordination and Strategy Unit, CDC. “In fact, resistance has even been detected before FDA approval. To save lives and protect people, it is vital to make technology accessible to hospital labs nationwide. We hope this pilot will help ensure our newest drugs last longer and put gold-standard lab results in healthcare providers’ hands faster.”

In other words, the hope with the new pilot program is that the HP bioprinters will enable hospitals to speed up antimicrobial susceptibility testing to ensure that a particular drug is actually effective. By installing the bioprinters at various facilities, the testing can be conducted regularly and locally which can increase the overall performance of antibiotic treatments in patients.

HP bioprinters CDC

Again, despite HP’s well known 3D printing MJF platform, its bioprinting system functions more in two dimensions. In short, the machine dispenses molecules and biomolecules (at a picoliter to microliter scale). This method can reportedly be used for drug discovery, genomics and proteomics research.

Through its collaboration with the CDC, HP will offer its bioprinters to labs in New York, Minnesota, Tennessee and Wisconsin in early 2019. Understandably, the pilot program will first target testing for highly resistant bacteria strains. Pan-resistant bacteria (meaning bacteria resistant to most antimicrobial agents) will be the first thing to be tackled.

Going forward, HP will continue to collaborate with the CDC to evaluate and refine the pilot project and, down the line, explore the possibility of extending it nationwide.

Tags

Tess Boissonneault

Tess Boissonneault moved from her home of Montreal, Canada to the Netherlands in 2014 to pursue a master’s degree in Media Studies at the University of Amsterdam. It was during her time in Amsterdam that she became acquainted with 3D printing technology and began writing for a local additive manufacturing news platform. Now based in France, Tess has over two and a half years experience writing, editing and publishing additive manufacturing content with a particular interest in women working within the industry. She is an avid follower of the ever-evolving AM industry.

Related Articles

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • PHPSESSID
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services
Close
Close

STAY AHEAD

OF THE CURVE

Join industry leaders and receive the latest insights on what really matters in AM!

This information will never be shared with 3rd parties

I’ve read and accept the privacy policy.*

WELCOME ON BOARD!